IPO - Kraig Biocraft Laboratories, Inc

Form Type: POS AM

Filing Date: 2025-04-17

Corporate Action: Ipo

Type: Update

Accession Number: 000164117225005266

Filing Summary: Kraig Biocraft Laboratories, Inc. has filed a Post-Effective Amendment No. 1 to its Form S-1 registration statement with the SEC. This amendment pertains to an offering of up to 207,787,193 shares of common stock by YA II PN, Ltd., a selling stockholder under a standby equity purchase agreement dated January 21, 2025. Under this agreement, the Selling Stockholder has committed to purchase up to $10 million of common stock at the company's discretion. The amendment updates previously filed information regarding the resale of shares and the current state of offerings under the Securities Act of 1933. It also includes the director and executive contact information along with specifics of the agreement. The registration statement's effectiveness is contingent upon the filing of necessary amendments or additional disclosures, and there are potential risks associated with the sale of shares impacting the market price of the company's stock.

Form Type: S-1/A

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225006667

Filing Summary: This document is Pre-Effective Amendment No. 2 to the Registration Statement on Form S-1 for Kraig Biocraft Laboratories, Inc. The filing date is February 14, 2025, and it indicates that the company intends to register securities for sale to the public, effective as soon as practicable following this filing. This amendment specifically includes the facing page, explanatory note, certain items of the registration statement, and the signature page, with all other parts of the registration statement remaining unchanged. There are no additional securities being registered under this Pre-Effective Amendment. The filing confirms the company's status as a smaller reporting company and emerging growth company under SEC definitions. The estimated expenses expected to be incurred in connection with the issuance and distribution of the securities have also been referenced, although specific amounts for legal, accounting, and miscellaneous expenses are to be determined by subsequent amendments. The document summarizes recent sales of unregistered securities, which include structured convertible transactions with investors. The conversion of these securities into common stock and associated warrants is contingent upon specific terms relating to pricing and ownership limits. The obligations of the company in these agreements are secured by various guarantees and securities agreements.

Form Type: S-1/A

Filing Date: 2025-02-13

Corporate Action: Ipo

Type: New

Accession Number: 000149315225006482

Filing Summary: This document represents Pre-Effective Amendment No. 1 to the Registration Statement on Form S-1 for Kraig Biocraft Laboratories, Inc., filed with the SEC on February 7, 2025. This amendment includes the facing page, explanatory note, specific new exhibits, and other necessary components for the registration process. The registrant describes several aspects including its principal offices in Ann Arbor, Michigan, and confirms that it is classified as a smaller reporting and non-accelerated filer. It emphasizes that the effective date of this registration will be clarified in future amendments, and approximately $1,531 in SEC registration fees was previously paid. The document does not register any additional securities but focuses on maintaining compliance as they move toward offering their common stock to the public. The company attests to its financial structure and previous sales of unregistered securities, outlining associated expenses and agreements with third parties, particularly Yorkville, concerning convertible debentures and warrants. The company aims to provide shares of common stock upon effectiveness of this registration statement and outlines indemnification provisions for its directors and officers.